Micronization of a poorly water-soluble drug, fenofibrate, via supercritical-fluid-assisted spray-drying

다국어 초록 (Multilingual Abstract)

Purpose In the present study, fenofibrate (a model drug with poor aqueous solubility) was micronized using the supercriticalfluid- assisted spray-drying (SA-SD) process to improve dissolution and biopharmaceutical property.
Methods Solid-state characterizations including particle size analysis and dissolution test were carried out. To identify the main effects of SA-SD process parameters (such as pressure, temperature, concentration of drug solution, supercritical carbon dioxide (SC-CO2) injection rate, and drug solution injection rate) on the morphology and particle size distribution of micronized fenofibrate particles, a 27−3 IV fractional factorial screening design was employed. Moreover, the effect of improved dissolution rate via micronization using SA-SD technology on the biopharmaceutical properties of fenofibrate was evaluated in a pharmacokinetic (PK) study in Sprague–Dawley rats.
Results The results of the screening design showed that the mean particle size and distribution can be controlled by manipulating the drug solution concentration and CO2 injection rate. The SA-SD process resulted in a significant decrease in mean particle size (1.8–8.33 μm), as compared with that of unprocessed fenofibrate (24.2 ± 0.8 μm). There was a significant enhancement in the dissolution rate of micronized fenofibrate particles smaller than 5 μm compared to that of unprocessed fenofibrate. Moreover, an in vivo PK study in Sprague–Dawley rats showed that the increased dissolution rate improved biopharmaceutical properties (larger area under the curve and maximum serum concentration) of micronized fenofibrate than those of unprocessed fenofibrate.
Conclusion Therefore, the SA-SD process is a useful micronization technology for improving both physicochemical and biopharmaceutical properties of poorly water-soluble drugs.

참고문헌 (Reference)

1 World Health Organization, "WHO model list of essential medicines, 22nd list"

2 Heinz A, "Understanding the solid-state forms of fenofibrate—a spectroscopic and computational study" 71 (71): 100-110, 2009

3 Lu Y, "Understanding the relationship between wettability and dissolution of solid dispersion" 465 : 25-31, 2014

4 Benet LZ, "The use of BDDCS in classifying the permeability of marketed drugs" 25 : 483-488, 2008

5 Noyes A, "The rate of solution of solid substances in their own solutions" 19 : 930-934, 1987

6 Pasquali I, "Swelling, melting point reduction, and solubility of PEG 1500 in supercritical CO2" 356 : 76-81, 2008

7 Yang B, "Surface wettability modulated by surfactant and its effects on the drug release and absorption of fenofibrate solid dispersions" 20 : 1-10, 2019

8 Meziani MJ, "Supercritical-fluid processing technique for nanoscale polymer particles" 3 : 704-707, 2004

9 Reverchon E, "Supercritical-assisted atomization to produce micro-and/or nano particles of controlled size and distribution" 41 : 2405-2111, 2002

10 Kankala RK, "Supercritical fluid(SCF)-assisted fabrication of carrier-free drugs : an eco-friendly welcome to Active Pharmaceutical Ingredients(APIs)" 176 : 113846-, 2021

11 Moshashaee S, "Supercritical fluid processing of proteins : lysozyme precipitation from aqueous solution" 55 : 185-192, 2003

12 Reverchon E, "Supercritical antisolvent micronization of cefonicid : thermodynamic interpretation of results" 31 : 207-215, 2004

13 Chattopadhyay P, "Supercritical CO2based production of magnetically responsive micro-and nano-particles for drug targeting" 41 : 6049-6058, 2002

14 McClellan AK, "Seperating polymer solutions with supercritical fluids" 18 : 674-681, 1985

15 Savla R, "Review and analysis of FDA approved drugs using lipid-based formulations" 43 : 1743-1758, 2017

16 Young TJ, "Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs" 16 : 402-407, 2000

17 Maltesen MJ, "Quality by design–Spray drying of insulin intended for inhalation" 70 : 828-838, 2008

18 Elvassore N, "Production of insulin-loaded poly(ethylene glycol)/poly(l-lactide)(PEG/PLA)nanoparticles by gas antisolvent techniques" 90 : 1628-1636, 2001

19 Falk RF, "Process variable implications for residual solvent removal and polymer morphology in the formation of Gentamycin-loaded poly(l-lactide)microparticles" 15 : 1233-1237, 1998

20 Kim M-S, "Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent(SAS)process" 69 : 454-465, 2008

21 Li X, "Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats" 35 : 827-833, 2009

22 Duarte ARC, "Preparation of controlled release microspheres using supercritical fluid technology for delivery of anti-inflammatory drugs" 308 : 168-174, 2006

23 Ghaderi R, "Preparation of biodegradable microparticles using solution-enhanced dispersion by supercritical fluids(SEDS)" 16 : 676-681, 1999

24 Lipinski C, "Poor aqueous solubility—an industry wide problem in drug discovery" 5 : 82-85, 2002

25 Kazarian S, "Polymer processing with supercritical fluids" 42 : 78-101, 2000

26 Kim J-S, "Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process" 359 : 211-219, 2008

27 Sethia S, "Physicochemical characterization of solid dispersion of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method" 91 : 1948-1957, 2002

28 Young T, "Phospholipid-stabilized nanoparticles of cyclosporine a by rapid expansion from supercritical to aqueous solution" 5 : 70-85, 2004

29 Hanafy A, "Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug" 59 : 419-426, 2007

30 Knez Z, "Particles formation and particle design using supercritical fluids" 7 : 353-361, 2003

31 Fages J, "Particle generation for pharmaceutical applications using supercritical fluid technology" 141 : 219-226, 2004

32 Loh ZH, "Overview of milling techniques for improving the solubility of poorly water-soluble drugs" 10 : 255-274, 2015

33 Moura C, "Optimization of supercritical CO2-assisted spray drying technology for the production of inhalable composite particles using quality-by-design principles" 357 : 387-397, 2019

34 Costa C, "Optimization of supercritical CO2-assisted atomization : phase behavior and design of experiments" 63 : 885-896, 2018

35 Pathak P, "Nanosizing drug particles in supercritical fluid processing" 126 : 10842-10843, 2004

36 Meziani M, "Nanoparticle formation in rapid expansion of water-in-supercritical carbon dioxide microemulsion into liquid solution" 34 : 91-97, 2005

37 Junghanns J-UA, "Nanocrystal technology, drug delivery and clinical applications" 3 : 295-, 2008

38 Rathbone MJ, "Modified release drug delivery technology" Marcel Dekker 2003

39 Snavely W, "Micronization of insulin from halogenated alcohol solution using supercritical carbon dioxide as an antisolvent" 91 : 2026-2038, 2002

40 Huang QP, "Micronization of gemfibrozil by reactive precipitation process" 360 : 58-64, 2008

41 Kim M-S, "Micronization of cilostazol using supercritical antisolvent(SAS)process : effect of process parameters" 177 : 64-70, 2007

42 Kim JA, "Microencapsulation of naproxen using rapid expansion of supercritical solutions" 12 : 650-661, 1996

43 Sievers RE, "Methods and apparatus for fine particle production" 5 : 639-, 1997

44 Hanna M, "Method and apparatus for the formation of particles. WO Patent WO95/001221"

45 Paudel A, "Manufacturing of solid dispersions of poorly water soluble drugs by spray drying : formulation and process considerations" 453 : 253-284, 2013

46 Hwang SJ, "Manufacturing method and apparatus of ultrafine particles having uniform particle size distribution" 8 : 734-, 2014

47 Weidner E, "Manufacture of powder coatings by spraying of gas-enriched melts" 24 : 529-533, 2001

48 Seckner AJ, "High solution behavior of the polymer-toluene-ethane system" 34 : 9-16, 1988

49 Wang Y, "Extraction and precipitation particles coating using supercritical CO2" 127 : 32-44, 2002

50 Abuzar SM, "Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent(SAS)process" 538 : 1-13, 2018

51 Kim M-S, "Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process : effect of various additives" 58 : 230-233, 2010

52 Cha K-H, "Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide" 7 : 5565-, 2012

53 Perrut M, "Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes : part I : micronization of neat particles" 288 : 3-10, 2005

54 Cho E, "Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives" 396 : 91-98, 2010

55 Porta G, "Engineering powder properties by supercritical fluid for optimum drug delivery. Part two : supercriticalassisted atomisation" 3 : 54-60, 2005

56 Cunha MSS, "Dissolution rate enhancement of the novel antitumoral beta-lapachone by solvent change precipitation of microparticles" 69 : 871-877, 2008

57 Vogt M, "Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying : comparison with commercial preparations" 68 : 283-288, 2008

58 Cho W, "Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes" 478 : 288-296, 2015

59 Ventosa N, "DELOS process : a crystallization technique using compressed fluids : 1. Comparison to the GAS crystallization method" 26 : 33-45, 2003

60 Lippold BC, "Correlation between wettability and dissolution rate of pharmaceutical powders" 28 : 67-74, 1986

61 Graser F, "Conditioning of finely divided crude organic pigments" 4 : 451-, 1982

62 Corrigan O, "Comparative physicochemical properties of hydrocortisone-PVP composites prepared using supercritical carbon dioxide by the GAS anti-solvent recrystallization process, by coprecipitation and by spray drying" 245 : 75-82, 2002

63 Lindenberg M, "Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system" 58 : 265-278, 2004

64 Lipinski C, "Avoiding investment in doomer drugs, is poor solubility an industry wide problem?" 4 : 17-19, 2001

65 Pasquali I, "Are pharmaceutics really going supercritical?" 364 : 176-187, 2008

66 Rodier E, "A three step supercritical process to improve the dissolution rate of Eflucimibe" 22 : 1-17, 2005

67 Amidon GL, "A theoretical basis for a biopharmaceutics drug classification : the correlation of in vitro drug product dissolution and in vivo bioavailability" 12 : 413-420, 1995

68 Ling H, "A review of currently available fenofibrate and fenofibric acid formulations" 4 : 47-, 2013

69 Guichard J, "A new formulation of fenofibrate : suprabioavailable tablets" 16 : 134-138, 2000